Active in the SBIR arena in the period 2003-2011, Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company structured around discovery and developy of novel cancer treatment products. Having proprietary, targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation, the firm's novel proprietary multi-kinase inhibitor -- ON 123300 -- targets CDK4/6 and other tyrosine kinases. The firm's product candidate oral rigosertib, which is in Phase 1 study of rigosertib in combination with a PD-1 inhibitor for patients with progressive K-Ras mutated non-small cell lung cancer; and in Phase 1b/2 for recessive dystrophic epidermolysis bullosa. More recently, the firm has been it involved in preclinical work investigating rigosertib in COVID-19. The company has a license agreement with SymBio Pharmaceuticals Limited; and license, development, and commercialization agreement with Pint International SA. Onconov
